Sunflower Therapeutics Announces the First System Delivery and Installation of the Daisy Petal™ Perfusion Bioreactor System to BioBuilder
MEDFORD, Mass.--(BUSINESS WIRE)-- Sunflower Therapeutics (Sunflower), a public benefit corporation transforming global access to protein manufacturing capacity for diverse applications, announced today the first system delivery and installation of its Daisy Petal™ Perfusion Bioreactor System to the BioBuilder Education Foundation, a nonprofit offering innovative ways to teach, learn, and explore cutting-edge science and engineering. This marks the first system delivery of the Daisy Petal™ in the United States, a significant step in the company's ongoing product commercialization.
The system is installed in the newly commissioned BioBuilder Learning Lab space in Allston Labworks for use in training local students, educators, and incumbent workers to be a passionate part of the growing biotechnology workforce.
"The bioeconomy is growing, and we need to be ready to manufacture our own biomolecules with cutting-edge protein manufacturing solutions. For the breadth of growth that the bioeconomy will need, we will require a large workforce,' said Dr. Kerry R. Love, Founder and CEO of Sunflower Therapeutics. "Sunflower is committed to supporting educational initiatives to grow the next generation of workers in our sector and there is no better place than Boston's vibrant biotech ecosystem to launch this effort. The Daisy Petal™ is the ideal tool—simple, intuitive, and user-friendly enough for a high school student to operate, yet robust and engineered to meet the rigorous demands of GMP process development and manufacturing."
Sunflower's innovative Daisy Petal™ perfusion fermentation system uses automation and know-how to replace complexity with simplicity. The single-use assembly is designed specifically for intuitive installation and a simple user experience. The Daisy Petal™ is a cutting-edge protein manufacturing solution that is the ideal tool for non-expert users to learn how to perform fermentation and expert users to maximize their efficiency.
'Having the Sunflower fermenter in our Allston Learning Lab ensures that local high school students can engage with the same tools and techniques used in industry," said Dr. Natalie Kuldell, founder and executive director of the BioBuilder Educational Foundation. "This instrument will expand our teaching capacity in ways that directly address gaps in the bioeconomy workforce, while also giving students a leg up and the foundation for great careers in biomanufacturing. We're not just teaching science - we're opening doors to meaningful careers."
The system's hardware and controls are engineered and optimized for in-vessel perfusion, utilizing a purpose-built disposable stirred tank reactor outfitted with a unique in-vessel perfusion device that enables greater volumetric productivity from the bench through scale-up manufacturing. With this approach, the system boasts space-time yield benefits five-to-ten times greater compared to traditional fed-batch methods for the production of diverse biomolecules, including biologic drugs, reagents, diagnostics, vaccines, foods, and other biologically derived materials.
BioBuilder's purchase of the Daisy Petal was made possible through a grant from the Massachusetts Life Sciences Center and other donors.
To learn more about Sunflower's accessible approach to bioprocessing, please visit sunflowertx.com.
About Sunflower Therapeutics
Sunflower Therapeutics is a unique biotech with a mission to transform bioeconomies worldwide by creating accessible solutions for protein product development and commercial manufacturing. Using our core technologies – an efficient host, data-driven methods for process development, and continuous biomanufacturing equipment – our team aims to democratize bioprocessing.
About BioBuilder
Created by an award-winning team from MIT, BioBuilder is a nonprofit helping educate a future-ready workforce that will solve some of the world's greatest challenges by bringing tomorrow's science into today's classrooms. BioBuilder has worked with schools in over 55 countries and 49 states, impacting over 63,000 students. By inspiring students and educators to learn and love science, we equip the next generation through experiential learning opportunities tailored to high school students. Through in-classroom, after school, and dedicated cohort programs, we are providing exposure to real-world STEM applications to students in urban, rural and underserved communities. By matching our curriculum with the needs of the biotech industry, our goal is to bring BioBuilder to every school in America. For more information about BioBuilder, visit www.biobuilder.org.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
44 minutes ago
- Business Wire
Northern Trust Appointed Custodian for Dutch Pension Fund BPF Beton
AMSTERDAM--(BUSINESS WIRE)--Northern Trust (Nasdaq: NTRS) announced today that it has been appointed by Dutch pension fund BPF Beton to provide global custody, regulatory reporting, valuation and accounting, and performance analytics. BPF Beton is the industry pension fund for people working in the concrete products industry in the Netherlands with approximately EUR 1.2 billion (approximately US$1.2 billion) in assets as at 31 December 2024. Herman Prummel, country head, Netherlands, Northern Trust, said: 'We are pleased to be supporting BPF Beton. Northern Trust has been servicing Dutch pension clients for four decades and is a long-term strategic partner to the pensions industry. With our deep local market expertise, global scale, data and technology platform, Northern Trust is committed to the Dutch pensions industry and its evolving needs. This mandate showcases our regional commitment and expertise in ensuring a seamless, efficient transition to the new reporting standards. We look forward to working with BPF Beton and continuing to serve the needs of the Dutch pension fund industry.' The pension system in the Netherlands is migrating to a defined contribution system, known as the Future of Pensions Act or 'Wet Toekomst Pensioenen'. BPF Beton sought an asset servicing partner that could help them through the changes brought on by the new legislation. Govert van der Peijl, president and chairman of BPF Beton, said: 'This transition is complex and large scale. We sought a strategic service provider who understands the requirements under the new legislation and who can support us navigate this new landscape. Northern Trust impressed us with their rapid response to the new legislation and their dedication to the Dutch pension fund industry. We are pleased to collaborate with Northern Trust and look forward to their support as our scheme embarks on the next chapter of its journey to deliver the best possible outcomes for our members.' About BPF Beton BPF Beton is the sectoral pension scheme for employees active in the manufacturing industry for concrete products. Based in Amsterdam, they represent over 25,000 members as at 31 December 2024. About Northern Trust Northern Trust Corporation (Nasdaq: NTRS) is a leading provider of wealth management, asset servicing, asset management and banking to corporations, institutions, affluent families and individuals. Founded in Chicago in 1889, Northern Trust has a global presence with offices in 24 U.S. states and Washington, D.C., and across 22 locations in Canada, Europe, the Middle East and the Asia-Pacific region. As of March 31, 2025, Northern Trust had assets under custody/administration of US$16.9 trillion, and assets under management of US$1.6 trillion. For more than 135 years, Northern Trust has earned distinction as an industry leader for exceptional service, financial expertise, integrity and innovation. Visit us on Follow us on Instagram @northerntrustcompany or Northern Trust on LinkedIn. Northern Trust Corporation, Head Office: 50 South La Salle Street, Chicago, Illinois 60603 U.S.A., incorporated with limited liability in the U.S. Global legal and regulatory information can be found at
Yahoo
an hour ago
- Yahoo
Press Release Biocartis NV: Biocartis Announces IVDR Class C CDx Certification of the Idylla™ EGFR Mutation Test
PRESS RELEASE 02/06/2025, 10:00 CEST Biocartis Announces IVDR Class C CDx Certification of the Idylla™ EGFR Mutation Test Mechelen, Belgium, 02 June 2025 – Biocartis NV ('Biocartis'), an innovative molecular diagnostics company, is pleased to announce that its Idylla™ EGFR Mutation Test has received the European Union (EU) Technical Documentation Assessment and Quality Management System certificate under the European In Vitro Diagnostic Medical Device Regulation (EU) 2017/746 (IVDR), making it the first Idylla™ Test to be certified as a Class C Companion Diagnostic (CDx) IVD Medical Device under the IVDR framework. The IVDR-certified Idylla™ EGFR Mutation Test is designed to serve as a CDx for the detection of EGFR exon 19 deletions and the L858R mutation, which are key biomarkers that guide targeted therapies for patients with non-small cell lung cancer (NSCLC). The IVDR certification confirms the Test's compliance with Europe's rigorous new regulatory standards, ensuring enhanced patient safety, improved information transparency, and robust data traceability. Designed for use on the Idylla™ Platform, the Test qualitatively detects 44 mutations across exons 18, 19, 20, and 21 of the EGFR gene – all within a single cartridge. Among these, exon 19 deletions and L858R mutations are validated as CDx targets, and the remaining mutations have been analytically validated. Utilizing formalin-fixed, paraffin-embedded (FFPE) tissue samples, the Test is fully automated from sample to result, delivering fast results in under 3 hours – streamlining laboratory workflows and empowering oncologists with timely treatment decisions for their patients. With 99.2% sensitivity (PPA) and 99.0% specificity (NPA) for the CDx targets, the Idylla™ EGFR Mutation Test ensures accurate detection of key EGFR mutations, providing healthcare professionals with actionable results to guide treatment decisions in NSCLC. For more information about the Test, please visit the Biocartis website or contact the Biocartis team. While the IVDR-certified Idylla™ EGFR Mutation Test is now available to customers across Europe, with availability in other non-US markets expected to follow progressively – Biocartis is also developing the Idylla™ EGFR CDx Test in the US with AstraZeneca. Upon approval, the Test will be intended to help identify patients with NSCLC who may respond to treatment with Tagrisso® (Osimertinib), AstraZeneca's third-generation EGFR-TKI treatment. Roger Moody, Chief Executive Officer of Biocartis, commented: 'Achieving IVDR certification for our Idylla™ EGFR Mutation Test is a key milestone for Biocartis and reinforces our commitment to quality and regulatory excellence. This is the first Idylla™ Test to be certified under the new IVDR framework, and we are currently pursuing certification of additional Tests in our portfolio. The IVDR establishes more rigorous standards to improve patient safety and diagnostic accuracy, and we are proud to be at the forefront of this evolution in European diagnostics.' ----- END ----- More information: info@ Biocartis NV. Generaal De Wittelaan 11B, 2800 Mechelen, Belgium About Biocartis With its revolutionary and proprietary Idylla™ Platform, Biocartis aspires to enable personalized medicine for patients around the world through universal access to molecular testing, by making molecular testing actionable, easy, fast and suitable for any lab. The Idylla™ Platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) based system designed to offer in-house molecular biomarker testing in only 3 hours, allowing fast and optimal treatment selection. Idylla™'s continuously expanding menu of molecular diagnostic tests and research assays addresses key unmet clinical needs. Today, Biocartis offers tests supporting lung, skin, thyroid, colorectal, endometrial, blood, brain and breast cancer. More information: Follow us on LinkedIn, Facebook and X (Twitter). Disclaimers Idylla™ Platform is CE-marked in Europe in compliance with EU IVD Regulation 2017/746, listed as a class II device in the US under establishment registration 3009972873, and registered in many other countries. Idylla™ EGFR Mutation Test (A0270/6) is CE-marked in Europe in compliance with the EU IVD Regulation 2017/746 (IVDR). Biocartis and Idylla™ are registered trademarks in Europe, the US and many other countries. The Biocartis and Idylla™ trademarks and logos are used trademarks owned by Biocartis NV. © June 2025, Biocartis NV. All rights lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
Business Wire
an hour ago
- Business Wire
3D Investment Partners Sends Open Letter to the Board of NS Solutions
TOKYO--(BUSINESS WIRE)--3D Investment Partners Pte. Ltd. ('3D' or 'we'), an independent investment management firm providing discretionary investment services to a fund that is the largest minority shareholder of NS Solutions Corporation ('NSSOL' or the 'Company,' TSE Code: 2327.T), is committed to Japan-focused value investing with an investment philosophy centered on mid- to long-term value creation through compound capital growth. Today, we have sent an open letter to NSSOL, and we would like to share an overview of its contents. In the open letter, we disclosed the results of a survey of market participants (the 'Survey') conducted by an independent third-party research firm. The Survey revealed that a significant number of respondents share the following views: 1 64% of respondents answered 'Yes' to the question: 'Do you believe that NSSOL's corporate value and the interests of minority shareholders are being impaired by its parent company, Nippon Steel?' 100% of respondents answered 'No' to the question: 'Do you believe that NSSOL's outside directors are adequately fulfilling their role as representatives and advocates of shareholders?' 90% of respondents answered 'No' to the question: 'Do you believe that NSSOL's current Board of Directors maintains sufficient independence from Nippon Steel?' 72% of respondents answered 'No' to the question: 'Do you believe that NSSOL's new medium-term management plan sufficiently addresses the issue of value erosion caused by Nippon Steel?' These results suggest that many market participants share the same concerns that we have long held with respect to NSSOL. We have consistently pointed out that NSSOL's corporate value is being impaired due to its lack of full independence from its parent company, Nippon Steel. This includes various concerns identified in the Survey, such as economically irrational value erosion from transactions with Nippon Steel—such as low-interest deposits—as well as fundamental issues with the current Board of Directors and the inadequacies of the new medium-term plan. Based on the results of the Survey, we have reiterated our request that NSSOL's Board of Directors establish a special committee composed solely of independent outside directors to conduct a comprehensive and fundamental review, including a reassessment of NSSOL's relationship with Nippon Steel, with the aim of maximizing corporate value. In the open letter, we also presented more concrete proposals directed at NSSOL. We encourage all shareholders to share with us any views or feedback they may have. We would also be grateful if shareholders would refer to the materials provided as they consider how to exercise their voting rights at the upcoming Annual General Meeting, and as they engage in future dialogue with NSSOL. We remain firmly committed to pursuing constructive engagement with NSSOL to enhance corporate value—grounded in the candid perspectives of shareholders. 【Letter to the Board of Directors】 June 2, 2025 〒105-6417 Toranomon Hills Business Tower 1-17-1 Toranomon, Minato-ku, Tokyo 105-6417, Japan NS Solutions Corporation To: Representative Director Kazuhiko Tamaoki Board of Directors 1 Temasek Avenue #20-02A, Millenia Tower, Singapore 3D Investment Partners Pte. Ltd. Dear Members of the Board, We commissioned an independent third-party research firm to conduct a perception survey (the 'Survey') of market participants regarding NS Solutions Corporation ('NSSOL' or the 'Company') between April and May 2025. We were not involved in the interviews, feedback analysis, report preparation or summarization of key findings, all of which were conducted exclusively by the independent research firm. Accordingly, we had no influence on the Survey results. The Survey targeted a broad range of buy-side and sell-side analysts, both domestic and international, and we are highly confident in the objectivity of its findings. The results of the Survey are summarized in Appendix 1. The findings indicate that many market participants share the following views regarding NSSOL: The corporate value of NSSOL and the interests of its minority shareholders are being impaired by its parent company, Nippon Steel. NSSOL's outside directors are not fulfilling their role of representing and advocating for minority shareholders. The current Board of Directors of NSSOL lacks sufficient independence from NSSOL's parent company. NSSOL's new medium-term management plan does not adequately address the issue of exploitation by the parent company. These results demonstrate that many market participants share our concerns regarding NSSOL. We have long pointed out that NSSOL's corporate value is being impaired due to the lack of full independence from its parent company, Nippon Steel. The issues we have identified include economically irrational value erosion from transactions with Nippon Steel—such as low-interest deposits—as well as the lack of independence of the current Board of Directors (the 'Board') and the insufficiency of the new medium-term plan, all of which are reflected in the Survey findings. In its new medium-term management plan, NSSOL has announced that outside directors will comprise a majority of the Board following the June 2025 Annual General Meeting. However, the results of the Survey indicate that a significant majority of market participants believe that the outside directors are not fulfilling their role of representing and advocating for minority shareholders. This clearly demonstrates that simply establishing a formal majority of outside directors is insufficient to assure market participants that the Board has developed a robust supervisory function over management. In light of the concerns identified through the Survey, we hereby reiterate our request that NSSOL establish a special committee composed solely of independent outside directors to conduct a comprehensive review aimed at maximizing corporate value, including a reassessment of the Company's relationship with Nippon Steel. If this review is led by independent outside directors, it would ensure independence from the Nippon Steel and enable a fundamental review of the relationship with the parent company. This, in turn, would allow for a resolution of the current situation in which NSSOL's value is being impaired and the interests of minority shareholders undermined. In addition, conducting the review with objectivity and transparency, under the oversight of independent outside directors, would allow NSSOL to restore confidence in market participants of the Board's independence. To achieve the intended outcomes, the special committee must meet the following criteria: It must be a committee under the direct authority of the Board, composed exclusively of independent outside directors, to ensure independence from Nippon Steel. The scope of the review must include at minimum: (i) Quantitative assessment of the value erosion resulting from the current relationship with Nippon Steel and consideration of concrete remedies. (ii) Quantitative assessment of the growth potential currently constrained by the relationship with Nippon Steel and consideration of how to realize that potential. (iii) Quantitative assessment and consideration of other areas for value enhancement that remain unrealized due to the lack of independence from Nippon Steel and the absence of a KPI-driven management approach focused on maximizing corporate and shareholder value. To ensure the committee's effectiveness, a working group should be formed to support its operation, and a financial advisor with a proven track record in enhancing corporate value should be appointed. In line with discussions in the 'Study Group on Minority Shareholder Protection in Subsidiary Listings' and the Tokyo Stock Exchange's December 26, 2023 guidelines on 'Enhancing Disclosure on Minority Shareholder Protection and Group Governance,' the committee should produce results within a reasonable period and disclose both the review process and its findings with sufficient transparency. The above constitutes our current request to the Board. We respectfully ask that you inform us by June 30, 2025, whether you are willing to establish such a special committee. [Appendix 1] Survey Results 1. On the relationship with Nippon Steel 64% of respondents answered 'Yes' to the question: 'Do you believe that NSSOL's corporate value and the interests of its minority shareholders are being impaired by its parent company, Nippon Steel?' 62% of respondents answered 'Yes' to the question: 'Do you believe that Nippon Steel's influence and control hinder NSSOL's management from maximizing corporate and shareholder value?' 100% of respondents answered 'No' to the question: 'Do you believe NSSOL provides adequate explanations to shareholders regarding transactions with Nippon Steel that may impair corporate value or minority shareholder interests?' 2. On Outside Directors 84% of respondents answered 'No' to the question: 'Do you believe NSSOL's outside directors engage in sufficient dialogue and interaction with shareholders?' 67% of respondents answered 'No' to the question: 'Do you believe NSSOL's outside directors appropriately supervise conflicts of interest between Nippon Steel and minority shareholders?' 100% of respondents answered 'No' to the question: 'Do you believe NSSOL's outside directors adequately fulfill their role in representing and advocating for shareholders?' 3. On the Board of Directors 90% of respondents answered 'No' to the question: 'Do you believe that NSSOL's current Board of Directors maintains sufficient independence from Nippon Steel?' 4. On the New Medium-Term Management Plan 72% of respondents answered 'No' to the question: 'Do you believe that NSSOL's new medium-term management plan sufficiently addresses exploitation by the parent company, Nippon Steel?' Note: The above percentages have been calculated by excluding responses marked 'No opinion' and rounding to the nearest whole number. About 3D Investment Partners Pte. Ltd. 3D Investment Partners Pte. Ltd. is an independent Singapore-based Japan focused value investing fund manager founded in 2015. 3D Investment Partners Pte. Ltd. focuses on partnering with managements who share its investment philosophy of medium- to long-term value creation through compound capital growth and a common objective of achieving long-term returns. Disclaimer This press release is provided for informational purposes only and does not constitute an offer to purchase or sell any security or investment product, nor does it constitute professional or investment advice. This press release should not be relied on by any person for any purpose and is not, and should not be construed as investment, financial, legal, tax or other advice. 3D Investment Partners Pte. Ltd. and its affiliates and their related persons ('3DIP') believe that current market price of NSSOL does not reflect its instinct value. 3DIP acquired beneficially and/or economic interest based on its own idea that NSSOL securities have been undervalued and provides attractive investment opportunity and may in the future beneficially own and/or have an economic interest in, NSSOL securities. 3DIP intends to review its investments in the NSSOL on a continuing basis and, depending upon various factors including, without limitation, the NSSOL's financial position and strategic direction, the outcome of any discussions with NSSOL, overall market conditions, other investment opportunities available to 3DIP, and the availability of NSSOL securities at prices that would make the purchase or sale of NSSOL securities desirable, 3DIP may, from time to time (in the open market or in private transactions), buy, sell, cover, hedge, or otherwise change the form or substance of any of its investments (including the investment in NSSOL securities) to any degree in any manner permitted by any applicable law, and expressly disclaims any obligation to notify others of any such changes. No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness, or reliability of the information contained herein, nor is it intended to be a complete statement or summary of the securities, markets, or developments referred to herein. 3DIP expressly disclaims any responsibility or liability for any loss howsoever arising from any use of, or reliance on, this press release or its contents as a whole or in part by any person, or otherwise howsoever arising in connection with this press release. 3DIP hereby expressly disclaims any obligation to update or provide additional information regarding the contents of this press release or to correct any inaccuracies in the information contained in this press release. 3DIP disclaims any intention or agreement to be treated as a joint holder (kyodo hoyu sha) under the Financial Instruments and Exchange Act of Japan, a closely related party (missetsu kankei sha) under the Foreign Exchange and Foreign Trade Act with other shareholders, or receiving any power or permission to represent other shareholders in relation to the exercise of their voting rights, and has no intention to solicit, encourage, induce or require any person to represent such voting rights. 3DIP does not have the intention to make a proposal, directly or through other shareholders of NSSOL, to transfer or abolish the business or asset of NSSOL and/or NSSOL group companies at the general shareholders meeting of NSSOL. 3DIP does not have the intention and purpose to engage in any conduct which constricts the continuing and stable implementation of business of NSSOL and/or NSSOL group companies. This press release may include content or quotes from news coverage or other third party public sources ('Third Party Materials'). Permission to quote from Third Party Materials in this press release may neither have been sought nor obtained. The content of the Third Party Materials has not been independently verified by 3DIP and does not necessarily represent the views of 3DIP. The authors and/or publishers of the Third Party Materials are independent of, and may have different views to 3DIP. The quoting Third Party Materials on this press release does not imply that 3DIP endorses or concurs with any part of the content of the Third Party Materials or that any of the authors or publishers of the Third Party Materials endorses or concurs with any views which have been expressed by 3DIP on the relevant subject matter. The Third Party Materials may not be representative of all relevant news coverage or views expressed by other third parties on the stated issues. In respect of information that has been prepared by 3DIP (and not otherwise attributed to any other party) and which appear in the English language version of this press release, in the event of any inconsistency between the English language version and the Japanese language version of this press release, the meaning of the Japanese language version shall prevail unless otherwise expressly indicated. Expand 1 Percentages have been calculated by excluding respondents who answered 'No opinion,' and have been rounded to the nearest whole number.
